Skip to main content

Peer Review reports

From: Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer

Original Submission
8 Jun 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
7 Jul 2022 Reviewed Reviewer Report
2 May 2023 Reviewed Reviewer Report
8 May 2023 Author responded Author comments - Sini Li
Resubmission - Version 5
8 May 2023 Submitted Manuscript version 5
9 May 2023 Author responded Author comments - Sini Li
Resubmission - Version 6
9 May 2023 Submitted Manuscript version 6
9 May 2023 Author responded Author comments - Sini Li
Resubmission - Version 7
9 May 2023 Submitted Manuscript version 7
8 Jun 2023 Reviewed Reviewer Report
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
21 Jun 2023 Editorially accepted
29 Jun 2023 Article published 10.1186/s12913-023-09728-6

You can find further information about peer review here.

Back to article page